FARMINGDALE, N.Y., Oct. 7 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with Neurotechnics Ltd., based in Banbury, England, for the distribution of the BoneScalpel(TM) Ultrasonic Bone Cutter.
The agreement provides Neurotechnics with the rights to sell in the United Kingdom and the Republic of Ireland, and includes minimum purchase requirements.
Neurotechnics is recognized as an innovative market leader in the distribution of state-of-the-art medical devices and capital equipment, with special emphasis in neuro and spine surgery.
The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the potential hazards associated with rotary sharps.
"Misonix welcomes Neurotechnics to our growing sales and distribution organization. Neurotechnics comes to us with an established reputation as a first tier distributor of advanced medical equipment in the United Kingdom and Ireland," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.
Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to
|SOURCE Misonix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved